Finance

Lists
CHRS:NASDAQ
Coherus Oncology Inc
USD 1,27
+0,40%
(+0,0050) 1D
USD 1,31
+3,00% (+0,038)
After hours
Closed: 7 Aug., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHRS...
Open
USD 1,27
High
USD 1,40
Low
USD 1,24
Mkt. cap
196,99 m
Avg. vol.
931,20 k
Volume
1,60 m
P/E ratio
0,76
52-wk high
USD 2,62
52-wk low
USD 0,81
EPS
USD 1,67
Beta
0,98
Shares outstanding
154,50 m
No. of employees
144
Open
USD 1,27
High
USD 1,40
Low
USD 1,24
Mkt. cap
196,99 m
Avg. vol.
931,20 k
Volume
1,60 m
P/E ratio
0,76
52-wk high
USD 2,62
52-wk low
USD 0,81
EPS
USD 1,67
Beta
0,98
Shares outstanding
154,50 m
No. of employees
144
News stories
From sources across the web
About Coherus Oncology Inc
CEODennis Lanfear
Employees144
Founded2010
HeadquartersRedwood City, Kalifornië, Verenigde State van Amerika
Sector-
Websitecoherus.com
Analyst ratings
Based on 5 analysts giving stock ratings to CHRS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CHRS in the last 3 months.
Highest
Current USD 1,27
USD 10,00 (+687,40%)
Average
USD 7,75 (+510,24%)
Lowest
USD 4,00 (+214,96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
USD 4,00
+215%
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
USD 10,00
+687,4%
08/06/2026
Jay Olson
Oppenheimer
Buy
Maintained
USD 10,00
+687,4%
08/06/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
USD 7,00
+451,2%
08/06/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
-
-
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
11,57 m
12,75 m
12,31 m
14,31 m
Cost of goods sold
3,72 m
4,04 m
3,81 m
4,24 m
Cost of revenue
3,72 m
4,04 m
3,81 m
4,24 m
Research and development expenses
27,25 m
30,97 m
21,54 m
21,44 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22,83 m
21,01 m
23,10 m
20,95 m
Operating expense
50,08 m
51,98 m
44,65 m
42,40 m
Total operating expenses
53,80 m
56,03 m
48,46 m
46,64 m
Operating income
-42,23 m
-43,28 m
-36,15 m
-32,33 m
Other non operating income
2,14 m
-5,22 m
1,40 m
1,31 m
EBT including unusual items
-44,52 m
-46,35 m
-36,94 m
-33,35 m
EBT excluding unusual items
-42,42 m
-43,75 m
-36,94 m
-33,35 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35,53 m
-37,64 m
-38,33 m
-20,63 m
Net profit margin
-307,07%
-295,29%
-311,35%
-144,20%
Earnings per share
-0,33
-0,34
-0,25
-0,19
Interest and investment income
-
7,00 m
-
-
Interest expense
-2,32 m
-2,25 m
-2,19 m
-2,32 m
Net interest expenses
-2,32 m
4,75 m
-2,19 m
-2,32 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,27 m
-42,38 m
-35,27 m
-31,47 m
Gain or loss from assets sale
-
-338,32 m
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme